{"id":"W3087469327","doi":"10.1016/j.clml.2020.08.022","title":"Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; AstraZeneca France; Servier; Incyte; AbbVie; Genentech; Bayer; Celgene; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Roche","keywords":"Medicine; Idelalisib; Follicular lymphoma; Adverse effect; Oncology; PI3K/AKT/mTOR pathway; Clinical trial; Lymphoma; Targeted therapy; Internal medicine; Population; Cancer; Chronic lymphocytic leukemia; Ibrutinib; Leukemia","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008660462,0.0007118247,0.002019307,0.0009531965,0.0002127437,0.001166148,0.001170428,0.001065667,0.00714563],"category_scores_gemma":[0.001012633,0.0002284949,0.001008853,0.0008963631,0.0003531766,0.001567874,0.0007214755,0.002803298,0.002713562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006413284,"about_ca_system_score_gemma":0.001097761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001227466,"about_ca_topic_score_gemma":0.004311915,"domain_scores_codex":[0.9998065,0.00004031547,0.00002414345,0.00003171243,0.00006458498,0.00003268095],"domain_scores_gemma":[0.9997025,0.0001500041,0.00004204448,0.000006529498,0.00006725229,0.00003163959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002761685,0.00005645754,0.0001393166,0.009887921,0.0002002476,0.00007947384,0.00002103629,0.0001955695,0.0005678372,0.002742865,0.04039388,0.9454392],"study_design_scores_gemma":[0.0004035862,0.0002557298,0.0008531691,0.006497774,0.0004474287,0.0005510019,0.00004818043,0.000139347,0.0002242418,0.003407226,0.9871466,0.00002580396],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001120043,0.9979286,0.00006723893,0.0007925051,0.0003511395,0.000005314344,0.00003124027,0.000009550798,0.0007023905],"genre_scores_gemma":[0.0009449816,0.9966468,0.0001491608,0.001231476,0.0002984708,0.00001046715,0.00007675356,0.000002404821,0.000639462],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00714563,"threshold_uncertainty_score":0.02390456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05178835764682573,"score_gpt":0.3197734926016962,"score_spread":0.2679851349548705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}